GXMC
INSY

Global X Management Company’s Insys Therapeutics, Inc. INSY Stock Holding History

Global X Management Company’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-340
Closed -$4K – 1243
2017
Q1 		$4K Buy
340
+22
+7% +$234 ﹤0.01% 1190
2016
Q4 		$3K Hold
318
– – ﹤0.01% 1083
2016
Q3 		$4K Hold
318
– – ﹤0.01% 1081
2016
Q2 		$4K Buy
+318
New +$4.63K ﹤0.01% 966

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Global X Management Company's INSY Position: Q2 2017 in Review

Global X Management Company sold out of Insys Therapeutics, Inc. (INSY) in Q2 2017, closing a stake of 340 shares — an estimated $4K sold.

Global X Management Company first reported a position in INSY in Q2 2016 and held it in 4 quarters. The position peaked at $4K in Q1 2017. 118 funds tracked by Wall St. Rank hold INSY as of Q2 2017.

  • Global X Management Company reported no remaining Insys Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Global X Management Company sold 340 Insys Therapeutics, Inc. shares in Q2 2017, an estimated $4K.
  • Global X Management Company first reported a position in Insys Therapeutics, Inc. in Q2 2016 and held it in 4 quarters.
  • Global X Management Company's Insys Therapeutics, Inc. position peaked at $4K in Q1 2017.
  • 118 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2017.

Based on Global X Management Company's 13F filing for Q2 2017, filed 1 Aug 2017.